Virtual Patient Generation Strategies for Non-Alcoholic Fatty Liver Disease

Conference: ACoP
Software: NAFLDsym®
Division: DILIsym Services


Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are of growing concern within developed countries, with recent estimates suggesting up to 30% of the US population may be affected. NAFLDsym v2A is a QSP model of NAFLD and NASH that represents the primary pathophysiologic components of the disease, including steatosis, lipotoxicity, inflammation, dyslipidemia, and fibrosis. The model consists of a system of ordinary differential equations (ODEs) which describe these processes in the three primary acinar zones of the liver.

Weight gain is thought to play a substantial role in NAFLD/NASH disease progression. Steatosis, NAS, and fibrosis scores have been shown to correlate with weight gain , and improvement with each has also been reported with weight loss . NAFLDsym is capable of reproducing these behaviors.

By Fulya Akpinar Singh, Scott Q Siler , Grant T Generaux, Diane M Longo, Lisl Shoda, Christina Battista, Zackary R Kenz, Craig Thalhauser, Tarek Leil

Tenth Annual American Conference on Pharmacometrics (ACoP) Annual Meeting: October 19-22, 2019, Orlando, FL